Eagle Pharmaceuticals shares are trading lower after the company announced it will be delisted from the Nasdaq.
Portfolio Pulse from Benzinga Newsdesk
Eagle Pharmaceuticals is set to be delisted from the Nasdaq, leading to a decline in its share price.
October 02, 2024 | 1:22 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Eagle Pharmaceuticals announced its delisting from the Nasdaq, resulting in a decrease in its share price.
The delisting from Nasdaq is a significant event for Eagle Pharmaceuticals, as it affects the company's visibility and accessibility to investors, likely leading to a decrease in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100